Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Repurposing diphenylbutylpiperidine-class antipsychotic drugs for host-directed therapy of Mycobacterium tuberculosis and Salmonella enterica infections

Full text
Show less -
Heemskerk, M. T. [1] ; Korbee, C. J. [1] ; Esselink, J. J. [1] ; dos Santos, C. Carvalho [2, 1] ; van Veen, S. [1] ; Gordijn, I. F. [1] ; Vrieling, F. [1] ; Walburg, K. V. [1] ; Engele, C. G. [1] ; Dijkman, K. [3] ; Wilson, L. [1] ; Verreck, F. A. W. [3] ; Ottenhoff, T. H. M. [1] ; Haks, M. C. [1]
Total Authors: 14
[1] Leiden Univ, Med Ctr, Dept Infect Dis, Albinusdreef 2, NL-2333 ZA Leiden - Netherlands
[2] Inst Butantan, Lab Especial Desenvolvimento Vacinas, Sao Paulo - Brazil
[3] Biomed Primate Res Ctr, Dept Parasitol, TB Res Grp, Rijswijk - Netherlands
Total Affiliations: 3
Document type: Journal article
Source: SCIENTIFIC REPORTS; v. 11, n. 1 OCT 4 2021.
Web of Science Citations: 0

The persistent increase of multidrug-resistant (MDR) Mycobacterium tuberculosis (Mtb) infections negatively impacts Tuberculosis treatment outcomes. Host-directed therapies (HDT) pose an complementing strategy, particularly since Mtb is highly successful in evading host-defense by manipulating host-signaling pathways. Here, we screened a library containing autophagy-modulating compounds for their ability to inhibit intracellular Mtb-bacteria. Several active compounds were identified, including two drugs of the diphenylbutylpiperidine-class, Fluspirilene and Pimozide, commonly used as antipsychotics. Both molecules inhibited intracellular Mtb in pro- as well as anti-inflammatory primary human macrophages in a host-directed manner and synergized with conventional anti-bacterials. Importantly, these inhibitory effects extended to MDR-Mtb strains and the unrelated intracellular pathogen, Salmonella enterica serovar Typhimurium (Stm). Mechanistically Fluspirilene and Pimozide were shown to regulate autophagy and alter the lysosomal response, partly correlating with increased bacterial localization to autophago(lyso)somes. Pimozide's and Fluspirilene's efficacy was inhibited by antioxidants, suggesting involvement of the oxidative-stress response in Mtb growth control. Furthermore, Fluspirilene and especially Pimozide counteracted Mtb-induced STAT5 phosphorylation, thereby reducing Mtb phagosome-localized CISH that promotes phagosomal acidification. In conclusion, two approved antipsychotic drugs, Pimozide and Fluspirilene, constitute highly promising and rapidly translatable candidates for HDT against Mtb and Stm and act by modulating the autophagic/lysosomal response by multiple mechanisms. (AU)

FAPESP's process: 17/03332-5 - Advances in TB treatment: identification of biomarkers that predict treatment outcome and the molecular characterization of innate immune responses induced by rBCG-LTAK63
Grantee:Carina Carvalho dos Santos
Support Opportunities: Scholarships abroad - Research Internship - Doctorate (Direct)